The effect of increasing dialysate magnesium on calciprotein particles, inflammation and bone markers: post hoc analysis from a randomized controlled clinical trial.

What Was Tested

This randomized controlled trial looks at Vitamin D, K2, Magnesium and Zinc.

The formation of calciprotein particles (CPPs) may be an important component of the humoral defences against ectopic calcification.

Who Took Part

The study group was 57 subjects.

By PubMed's age tags, the people studied were middle-aged adults, older adults and people over 80, both men and women.

How the Study Was Run

The design is described as randomized, double-blind and parallel-group.

Because people in this Vitamin D, K2, Magnesium and Zinc study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the subjects and researchers unaware of who received Vitamin D, K2, Magnesium and Zinc.

The Vitamin D, K2, Magnesium and Zinc group and the comparison group ran side by side rather than switching.

CPP load, markers of systemic inflammation and bone turnover were measured at baseline and follow-up.

What Was Measured

PubMed files the paper under topics including Alkaline Phosphatase, Biomarkers, Bone and Bones, Calcium, Calcium Phosphates, Cytokines and Dialysis Solutions.

The authors tagged it with the keywords calciprotein particles, hemodialysis, inflammation and magnesium.

What This Means in Plain Language

The paper is a randomized, double-blind and parallel-group study of Vitamin D, K2, Magnesium and Zinc in 57 subjects.

Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2021 (Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association), a journal based in England.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.